Brodimoprim, a dihydrofolate reductase inhibitor, was introduced for the treatment of
common infections of upper respiratory tract such as sinusitis and exacerbation of chronic
bronchitis. It has a broad spectrum of antimicrobial activities against most Gram-positive and
-negative pathogens including some bacterial strains that are resistant to amoxicillin, a widely
used antibiotic for the indicated infections. Brodimoprim also has a favorable pharmacokinetic
profile exemplified by its long half-life and good tissue penetration.
